Ryan J. Brisson

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Tanguy Y. Seiwert, Corey C. Foster, Elizabeth A. Blair et al. · Annals of Oncology · 2018 · 233 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer

Victoria Villaflor, J.M. Melotek, Theodore Karrison et al. · Annals of Oncology · 2016 · 96 citations

Medicine, Oncology, Radiation Oncology +11

Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors

Corey C. Foster, Marcus Couey, Sara Kochanny et al. · Cancer · 2021 · 81 citations · Full text

Medicine, Immunology, Oncology +17

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience

Corey C. Foster, J.M. Melotek, Ryan J. Brisson et al. · Oral Oncology · 2018 · 55 citations

Medicine, Oncology, Radiation Oncology +7

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Sara Kochanny, Francis P. Worden, Douglas R. Adkins et al. · Cancer · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +15